Drug Profile
Lumiracoxib
Alternative Names: COX 189; Joicela; PrexigeLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis
- Class Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Acute pain; Dysmenorrhoea; Gout; Osteoarthritis
- No development reported Dental pain; Postoperative pain; Rheumatoid arthritis
Most Recent Events
- 31 Dec 2011 Discontinued - Phase-III for Osteoarthritis in Israel (PO)
- 31 Dec 2011 Discontinued - Phase-III for Osteoarthritis in South Africa (PO)
- 31 Dec 2011 Discontinued - Preregistration for Osteoarthritis in European Union (PO)